RESEARKA

The cited A/B receipts support a specific working claim: Use of metformin was associated with a significantly better overall and progression-free survival of patients with WHO grade III glioma (HR for OS = 0.30; 95% CI = 0.11-0.81); HR for PFS = 0.29; 95% CI = 0.11-0.78. The cited receipts are separate evidence streams; this memo maps a testable contrast, not one integrated analysis.

Citation Support

• source_1 Use of metformin and survival of patients with high‐grade glioma
• source_2 Metformin in elderly type 2 diabetes mellitus: dose-dependent dementia risk reduction
• source_3 Association Between Preadmission Metformin Use and Outcomes in Intensive Care Unit Patients With Sepsis and Type 2 Diabetes: A Cohort Study
• source_4 Metformin in the prevention of hepatocellular carcinoma in diabetic patients: A systematic review
• source_5 Metformin in Patients With COVID-19: A Systematic Review and Meta-Analysis